Key Highlights
- NextCure (NXTC) shares skyrocketed more than 300% Tuesday following the announcement of an all-stock merger agreement with privately-held Avere Therapeutics
- A simultaneous $320 million private placement financing round was led by major investors Fairmount and Hansoh Pharmaceutical
- Post-merger, the unified entity will list on Nasdaq under ticker symbol AVRX, with closure anticipated in late 2026
- Existing NextCure shareholders will retain roughly 1.21% ownership in the merged organization
- The transaction focuses on AVR-001, an innovative oral once-weekly IL-23 receptor antagonist for treating psoriasis and ulcerative colitis
Shares of NextCure (NXTC) surged more than 300% during Tuesday’s trading session after the clinical-stage biotechnology company revealed its merger plans with Avere Therapeutics, a private firm, in a transaction supported by $320 million in new capital.
While the single-day spike was dramatic, NXTC shares still trade approximately 84% lower year-to-date, entering the announcement with a modest market capitalization of only $7.87 million.
Under the all-stock arrangement, the merged organization will adopt the Avere Therapeutics identity and begin trading on Nasdaq with the AVRX ticker. Completion of the transaction is projected for the latter half of 2026.
The accompanying $320 million private placement encompasses $251 million in convertible debt instruments that will convert into equity upon deal closure. Investment leaders Fairmount and Hansoh Pharmaceutical spearheaded the financing, joined by Venrock Healthcare Capital Partners, General Atlantic, Janus Henderson Investors, and Wellington Management.
At the heart of this strategic combination sits Avere’s flagship candidate, AVR-001 — an orally administered, once-weekly IL-23 receptor antagonist under development for inflammatory diseases such as psoriasis and ulcerative colitis.
Avere recently secured licensing rights to AVR-001 from Hansoh for territories outside Greater China. The licensing agreement included a $120 million upfront payment to Hansoh, with potential additional milestone payments reaching $2.18 billion tied to development progress and sales achievements, alongside royalty obligations.
Proceeds from the new capital injection will support a Phase 2b clinical trial for psoriasis, launch of a Phase 3 psoriasis program, and initiation of a Phase 2b ulcerative colitis study. With a US IND already filed for AVR-001, Phase 2b trial commencement is slated for early 2027, with topline data anticipated during the first half of 2028.
Leadership Structure
Dr. Andrew Cheng, currently serving as Avere’s CEO, will assume leadership of the combined company as Chief Executive Officer, President, and Chairman of the Board. The executive team will include Kitty Yale as Chief Development Officer, William White in the CFO position, and Brett Pletcher serving as General Counsel.
Michael Richman, NextCure’s current Chief Executive, characterized the transaction as “a compelling opportunity” enabling shareholders to gain exposure to AVR-001’s clinical development trajectory.
Shareholder Considerations
Current NextCure shareholders will command approximately 1.21% ownership in the combined company — a reflection of NextCure’s present valuation compared to Avere.
Additionally, they will receive contingent value rights providing entitlement to 90% of net proceeds generated from any future monetization of NextCure’s current pipeline programs during a two-year period following transaction completion.
Tuesday’s trading activity exceeded 44 million shares, a dramatic increase from the typical three-month average daily volume of roughly 37,000 shares.
Analyst consensus on NXTC currently stands at Moderate Buy, supported by two Buy recommendations issued over the past three months, with a mean price target of $20 per share.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
